The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 3, 2008, Pages 459-466

  Dasbach, Erik J ^a   Insinga, Ralph P ^a   Yang, Yuh Cheng ^b,c   Pwu, Raoh Fang ^c   Lac, Christina ^d   Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Taiwan Branch   (Taiwan)

Author keywords

Cervical cancer; Cost effectiveness; Prevention; Quadrivalent HPV vaccine; Taiwan

Indexed keywords

EID: 67650917913     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. An HJ, Cho NH, Lee SY, et al (2003). Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer, 97, 1672-80.
2. Barnabas RV, Kulasingam SL (2007). Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoeconomics Outcomes Res, 7, 251-67.
3. Barnabas RV, Laukkanen P, Koskela P, et al (2006). Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med, 3, e138.
4. Bosch FX, Lorincz A, Muñoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
5. Brown DR, Schroeder JM, Bryan JT, et al (1999). Detection of multiple human papillomavirus types in Condylomata acuminate lesions from otherwise healthy and immunocompromised patients. J Clin Microbiol, 37, 3316-22.
6. Bureau of Health Promotion, Department of Health (2007). Cancer Registry Annual Report 2005. Taiwan, Republic of China: The Executive Yuan.
7. Bureau of Health Promotion, Department of Health (in press). Taiwan Pap Registry Annual Report 2005. Taiwan, Republic of China: The Executive Yuan.
8. Carter JJ, Madeleine MM, Shera K, et al (2001). Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res, 61, 1934-40.
9. Central Intelligence Agency. The World Factbook -Hungary. Retrieved in March 2008 from https://www.cia.gov/library/ publications/the-world-factbook/geos/tw.html#Econ.
10. Chen RJ, Lin YH, Chen CA, et al (1999). Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol, 73, 184-90.
11. Chou YC, Lee CH (2004). Analysis of women's health care utilization in Taiwan: Cesarean section, hysterectomy, service-specific and group-specific utilization rate. Final report. Taipei, Republic of China: Department of Health, Bureau of National Health Insurance.
12. Coste J, Pouchot J (2003). A grey zone for quantitative diagnostic and screening tests. Int J Epidemiol, 32, 304-13.
13. Cuzick J (2001). Time to consider HPV testing in cervical screening. Ann Oncol, 12, 1511-4.
14. Dasbach EJ, Elbasha EH, Insinga RP (2006). Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev, 28, 88-100.
15. Department of Health, National Health Insurance Annual Statistics Information Services, Executive Yuan, Taiwan, Republic of China, 2002. Retrieved in January 2008 from http://www.nhri.org.tw/nhird.
16. Department of Investment Services, MOEA (2008). http:// investintaiwan.nat.gov.tw/em/env/stats/per_capita_gdp.html
17. de Villiers EM, Fauquet C, Broker TR, et al (2004). Classification of papillomaviruses. Virology, 324, 17-27.
18. Elbasha EH, Dasbach EJ, Insinga RP (2007). Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis, 13, 28-41.
19. Elbasha EH, Galvani AP (2005). Vaccination against multiple HPV types. Math Biosci, 197, 88-117.
20. Franco EL, Mayrand MH, Trottier H (2006). Cervical cancer prevention. Promises and perils in a changing landscape. Oncol Exchange, 5, 9-13.
21. Freed GL, Derkay CS (2006). Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Pediatr Otorhinolaryngol, 70, 1799-803.
22. French KM, Barnabas RV, Lehtinen M, et al (2007). Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age-and sex-specific pattern of vaccination in Finland. Br J Cancer, 96, 514-8.
23. Goldie SJ, Grina D, Kohli M, et al (2003). A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer, 106, 896-904.
24. Hobbs CG, Sterne JA, Bailey M, et al (2006). Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol, 31, 259-66.
25. Huang LW, Hwang JL, Lin YH (2006). Type-specific distribution of human papillomavirus in relation to grades of cervical neoplasia. Int J Gynecol Obstet, 92, 143-4.
26. Insinga RP, Dasbach EJ, Elbasha EH, et al (2007). Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine, 26, 128-39.
27. Insinga RP, Dasbach EJ, Myers ER (2003). The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis, 36, 1397-403.
28. Insinga RP, Glass AG, Myers ER, et al (2007). Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making, 27, 414-22.
29. Joura EA, Leodolter S, Hernandez-Avila M, et al (2007). Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against highgrade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, 369, 1693-702.
30. Kodner CM, Nasraty S (2004). Management of genital warts. Am Fam Physician, 70, 2335-42.
31. Kulasingam SL, Myers ER (2003). Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA, 290, 781-9.
32. Lai HC, Sun CA, Yu MH, et al (1999). Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. Int J Cancer, 84, 553-7.
33. Maw RD, Reitano M, Roy M (1998). An international survey of patients with genital warts: perceptions regarding treatment and impact of lifestyle. Int J STD AIDS, 9, 571-8.
34. Merck & Co., Inc. (2007). Merck submits new cross-protection data for Gardasil® to the FDA and seeks new indications for vaginal and vulvar cancers. Retrieved in November 2007 from http://www.merck.com/newsroom/press_releases/product/2007_0417.html.
35. Ministry of the Interior, Republic of China (2004). Abridged life table in Taiwan-Fuchien area-female: 2004 [online]. Retrieved in September 2006 from http://sowf.moi.gov.tw/stat/english/elife/te935202.htm.
36. Mosciki AB, Shiboski S, Broering J, et al (1998). The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr, 132, 277-84.
37. Myers ER, Green S, Lipkus I (2004). Patient preferences for health states related to HPV infection: visual analogue scales vs time trade-off elicitation [abstract no. 390]. Proceedings of the 21st International Papillomavirus Conference; Mexico City, Mexico.
38. Palefsky JM (2007). HPV infections in men. Dis Markers, 23, 261-72.
39. Sanders GD, Taira AV (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis, 9, 37-48.
40. Shingleton HM, Patrick RL, Johnston WW, et al (1995). The current status of the Papanicolaou smear. CA Cancer J Clin, 45, 305-20.
41. Smith JS, Lindsay L, Hoots B, et al (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer, 121, 621-32.
42. Tang CH, Tsai IC, Pwu RF, et al (2006). Treatment costs of cervical precancerous lesion and cervical cancer in Taiwan. [abstract no. P-542]. 23rd International Papillomavirus Conference and Clinical Workshop; Prague, Czech Republic, 382.
43. Tseng CJ (2006). The 2003-2005 quality review for cervical cancer. Presented in the Bureau of National Health Insurance. Chia-Yi, Taiwan: Chang Gang Memorial Hospital.
44. US Food and Drug Administration. Gardasil (human papillomavirus vaccine). Retrieved in January 2008 from http://www.fda.gov/cber/products/gardasil.htm/
45. Villa LL, Costa RLR, Petta CA, et al (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus type 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 95, 1459 66.
46. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
47. World Health Organization (2007). Vaccinating against cervical cancer. Bull World Health Organ, 85, 89-90.
48. World Health Organization (WHO). Threshold values for intervention cost-effectiveness by region. Retrieved in March 2008 from http://www.who.int/choice/costs/CER_levels/en/index.html.
49. Wu CH, Lee MF, Chang MC, et al (1994). Detection of human papillomavirus types in cervical lesions of patients from Taiwan by the polymerase chain reaction. Sex Transm Dis, 21, 309-14.
50. Yang YY, Koh LW, Tsai JH, et al (2004). Correlation of viral factors with cervical cancer in Taiwan. J Microbiol Immunol Infect, 37, 282-7.